The higher risk may be due to the VEGF targeted agents, as they are commonly used in treating renal cell carcinoma and may increase the risk of developing autoimmune side effects38 due to inhibition of iodine uptake, hindrance of the proper functioning of VEGFR in the thyroid, or immune-mediated effects. The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.